- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04277793
Feasibility Evaluation of a Monitored Self-guided Cognitive Behavioural Therapy Digital Format
Feasibility Evaluation of a Monitored Self-guided Digital Cognitive Behavioural Therapy Format: an Uncontrolled Trial of a Problem Solving Intervention for Depression and Anxiety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective. The purpose of the study is to evaluate the feasibility of a new monitored self-guided digital cognitive behavioural therapy format through one of the key components of an intervention for depression and anxiety (Problem Solving) and to answer the question: Do patients with significant levels of depression and/or anxiety symptoms consider the monitored self-guided digital format usable and credible?
Background. Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events. It is one of the most well-examined therapeutic interventions for depression, with reliable support regarding symptom improvement in depression traditionally delivered with therapist-guidance when administered via the Internet. Since a new monitored self-guided digital intervention for depression and anxiety has been developed, including the key component Problem Solving, it is of importance to assess both the usability and treatment-credibility of this format to evaluate if it is feasible.
Methodology. Based on similar feasibility studies including around ten participants, a number of 16-30 participants will be included in this study to compensate for potential drop-outs. Participants will be recruited via a psychiatric clinic belonging to Stockholm County Council in Stockholm, Sweden, and will be patients in queue for treatment for depression and/or anxiety in a psychiatric setting. Inclusion criteria will be significant depression and/or anxiety symptoms. The participants included in the study will access the key component Problem Solving during four weeks while being on waitlist for regular treatment. They will be introduced to the intervention as a self-explanatory tool with possible beneficial effects on depression symptoms. Self-assessments will be carried out during the intervention. The scores on these scales will be compared to available published data from these scales from evaluations of therapist-guided Internet-based interventions if available, and otherwise data from these scales from studies on other digital interventions for mental health. The participants will also answer questions concerning their experience of the format.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Centrum för Psykiatriforskning
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Significant depression and/or anxiety symptoms measured with Patient Health Questionnaire (PHQ-9) and General Anxiety Disorder (GAD-7) (i.e. a PHQ-9 and/or GAD-7 score of ≥5).
Exclusion Criteria:
- insufficient Swedish knowledge
- minor (i.e. age <18 years)
- high suicide risk (i.e. a score ≥4 on the ninth item on the Montgomery Åsberg Depression Scale, MADRS-S)
- lack of access to a device with Internet connection (e.g. computer, mobile, tablet)
- lack of access to a phone on which calls and SMS can be received
- psychiatric or somatic problems that must be prioritized before or become an excessive obstacle to the intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Monitored self-guided problem solving intervention
|
Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
System Usability Scale
Time Frame: immediately after the intervention
|
Self-rated assessment of usability, higher score is better
|
immediately after the intervention
|
Treatment Credibility Scale
Time Frame: immediately after the intervention
|
Self-rated assessment of treatment credibility, higher score is better
|
immediately after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative Effects Questionnaire
Time Frame: immediately after the intervention
|
Self-rated assessment of negative treatment effects, lower score is better
|
immediately after the intervention
|
Negative Effects Questionnaire
Time Frame: During the intervention: 2 weeks from baseline
|
Self-rated assessment of negative treatment effects, lower score is better
|
During the intervention: 2 weeks from baseline
|
Patient Health Questionnaire - 9
Time Frame: Change from baseline immediately after the intervention
|
Self-rated depressive symptoms, lower score is better
|
Change from baseline immediately after the intervention
|
Generalized Anxiety Disorder - 7
Time Frame: Change from baseline immediately after the intervention
|
Self-rated anxiety symptoms, lower score is better
|
Change from baseline immediately after the intervention
|
System Usability Scale
Time Frame: During the intervention: 2 weeks from baseline
|
Self-rated assessment of usability, higher score is better
|
During the intervention: 2 weeks from baseline
|
Treatment Credibility Scale
Time Frame: During the intervention: 2 weeks from baseline
|
Self-rated assessment of treatment credibility, higher score is better
|
During the intervention: 2 weeks from baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of treatment format
Time Frame: During the intervention: 2 weeks from baseline
|
Written quantitative and qualitative questions concerning the treatment format
|
During the intervention: 2 weeks from baseline
|
Evaluation of treatment format
Time Frame: immediately after the intervention
|
Written quantitative and qualitative questions concerning the treatment format
|
immediately after the intervention
|
Interview concerning treatment format
Time Frame: immediately after the intervention
|
Phone interview with qualitative questions concerning the treatment format
|
immediately after the intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SVPSY290/19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Monitored self-guided problem solving
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research Institute; Children's Hospital Colorado; Nationwide... and other collaboratorsCompletedWounds and Injuries | Brain Injuries | Craniocerebral Trauma | Trauma, Nervous System | Brain Concussion | Head Injuries, Closed | Head Injury | Brain Edema | Disorders of Environmental Origin | Brain Hemorrhage, Traumatic | Subdural Hematoma | Epidural Hematoma | Intracranial Edema | Tbi | Cortical ContusionUnited States
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Istanbul UniversityCompleted
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedType 2 DiabetesUnited States
-
University of OttawaOttawa Hospital Research InstituteActive, not recruiting
-
Washington University School of MedicineNurses for Newborns FoundationCompletedPost-partum DepressionUnited States
-
Shengjing HospitalChina Medical University, ChinaRecruitingTwin; Complicating Pregnancy | PsychologyChina
-
VA Office of Research and DevelopmentCompletedDepression | AnxietyUnited States
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedMild Cognitive ImpairmentUnited States
-
Uskudar UniversityHacettepe UniversityCompletedDiabetes Mellitus, Type 2 | Occupational TherapyTurkey